Dynamic CT and Gadoxetic Acid-enhanced MRI Characteristics of P53-mutated Hepatocellular Carcinoma.

Background Imaging markers of hepatocellular carcinoma (HCC) on the basis of molecular classification are important for predicting malignancy grade and prognosis. P53-mutated HCC is a major aggressive subtype; however, its imaging characteristics have not been clarified. Purpose To clarify the imaging characteristics of P53-mutated HCC at dynamic CT and gadoxetic acid-enhanced MRI that are correlated with its clinical features, pathologic findings, and prognosis. Materials and Methods In this retrospective single-center study, patients with surgically resected HCC between January 2015 and May 2018 in a university hospital were evaluated. HCC was classified into P53-mutated HCC and non-P53-mutated HCC using immunostaining. Dynamic CT and gadoxetic acid-enhanced MRI findings, clinical features, pathologic findings, and prognosis were compared using Mann-Whitney test, χ2 test, multivariable regression analysis, receiver operating characteristic analysis, Kaplan-Meier method, and log-rank test. Immunohistochemical expression of P53, organic anion transporting polypeptide 1B3 (OATP1B3), and CD34 were evaluated, and the correlations were analyzed using the Pearson correlation test. Results In total, 149 patients (mean age, 67 years ± 9 [SD]; 103 men) with 173 HCCs were evaluated. P53-mutated HCC (n = 28) demonstrated higher serum α-fetoprotein (median, 127.5 ng/mL vs 5.5 ng/mL; P < .001), larger size (40.4 mm ± 29.7 vs 26.4 mm ± 20.5; P = .001), and higher rates of poorly differentiated HCC (22 of 28 [79%] vs 24 of 145 [17%]; P < .001). Dilated vasculature in the arterial phase of dynamic CT (odds ratio, 14; 95% CI: 3, 80; P = .002) and a lower relative enhancement ratio in the hepatobiliary phase (odds ratio, 0.05; 95% CI: 0.01, 0.34; cutoff value, 0.69; P = .002) independently predicted P53-mutated HCC. OATP1B3 expression and P53 expression were inversely correlated (P = .002; R = -0.24). Five-year overall survival was worse for P53-mutated HCC (50.0% vs 72.6%; P = .02). Conclusion Dilated vasculature at the arterial phase of dynamic CT and a lower relative enhancement ratio at the hepatobiliary phase of gadoxetic acid-enhanced MRI were useful markers for P53-mutated hepatocellular carcinoma with poor prognosis. © RSNA, 2022 Online supplemental material is available for this article.

[1]  A. Luciani,et al.  Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma. , 2020, Radiology.

[2]  S. Rebouissou,et al.  Advances in molecular classification and precision oncology in hepatocellular carcinoma. , 2020, Journal of hepatology.

[3]  Y. N. Park,et al.  Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma , 2020, Hepatology.

[4]  H. El‐Serag,et al.  Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.

[5]  A. Luciani,et al.  Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.

[6]  O. Matsui,et al.  Gadoxetic acid‐enhanced magnetic resonance imaging reflects co‐activation of β‐catenin and hepatocyte nuclear factor 4α in hepatocellular carcinoma , 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  C. Park,et al.  Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study. , 2017, Radiology.

[8]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[9]  D. Sinn,et al.  Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. , 2017, Journal of hepatology.

[10]  Xiaoshan Feng,et al.  Immunohistochemical Determination of p53 Protein Overexpression for Predicting p53 Gene Mutations in Hepatocellular Carcinoma: A Meta-Analysis , 2016, PloS one.

[11]  M. Sakamoto,et al.  Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. , 2016, Human pathology.

[12]  J. Yun,et al.  A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial–mesenchymal transition–independent manner , 2015, Hepatology.

[13]  O. Matsui,et al.  Hepatocellular Carcinoma with β-Catenin Mutation: Imaging and Pathologic Characteristics. , 2015, Radiology.

[14]  A. Tanimoto,et al.  OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. , 2014, Journal of hepatology.

[15]  Masakazu Yamamoto,et al.  Gd‐EOB‐DTPA‐enhanced magnetic resonance imaging and alpha‐fetoprotein predict prognosis of early‐stage hepatocellular carcinoma , 2014, Hepatology.

[16]  S. Arii,et al.  Contrast‐enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: Clinical and biological significance , 2013, Hepatology.

[17]  O. Matsui,et al.  Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. , 2012, Radiology.

[18]  Myeong-Jin Kim,et al.  Prediction of microvascular invasion of hepatocellular carcinoma: Usefulness of peritumoral hypointensity seen on gadoxetate disodium‐enhanced hepatobiliary phase images , 2012, Journal of magnetic resonance imaging : JMRI.

[19]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[20]  Y. Kanai,et al.  Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma , 2011, Cancer science.

[21]  O. Matsui,et al.  The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging , 2011, European Radiology.

[22]  Osamu Matsui,et al.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. , 2010, Radiology.

[23]  Sheng-Nan Lu,et al.  Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients , 2008, Journal of surgical oncology.

[24]  E. Lesaffre,et al.  The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin , 2006, Histopathology.

[25]  J. Manfredi,et al.  Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.